Shanghai Pharmaceuticals Holding Co., Ltd.

Zhixiong Xiang

Qian Wang

Guangxin Xia

Yanjun Liu

Yu Mao

Hui Ge

Yanan Han

Xiong Zhai

Guoyong Huo

Chen Shi

Xuemei Liao

The present invention discloses a substituted pyridine compound represented by formula I, and a pharmaceutically acceptable salt, stereoisomer and tautomer thereof. The compounds of the present invention are useful in the treatment of cancers. 

Substituted pyrimidines as cyclin-dependent kinase inhibitors

The present invention discloses a nitrogen-containing fused heterocyclic compound, as well as a preparation method, intermediate, composition and application thereof. The nitrogen-containing fused heterocyclic compound of the present invention as represented by formula (I), as well as the pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, metabolite or drug precursor thereof, exhibit a high selectivity and a high inhibitory activity with respect to CDK4 and CDK6 at a molecular level, an excellent inhibitory activity with respect to breast cancer cells at a cellular level, and significant inhibition of tumor cell proliferation associated with cyclin-dependent kinase activity at an animal level. The invention also exhibits a good stability with respect to human or mouse liver microsomes without significant inhibition of metabolic enzymes, good in vivo absorption in mice and rats, a high bioavailability and good druggability.

Growing community of inventors

Shanghai, China

Zhixiong Xiang